ClinicalTrials.gg
CompletedNCT02019472SIRROUND-HUpdated Oct 26, 2017Results posted

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

A Phase 3 interventional study of adalimumab 40 mg and sirukumab 100 mg in Arthritis, Rheumatoid, sponsored by Janssen Research & Development, LLC. Completed at 109 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-26.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
559
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
17th of 87
559 · median 160
Started
2014
with 3 others
Phase 3
36 of 87
1 open now
Registered
56th of 87
by date

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 17th largest by enrollment, is one of 4 that started in 2014, is one of 36 in phase 3, and was the 56th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.

Read the detailed description

This is a randomized, double-blind, parallel-group, global, multicenter study of subcutaneous (SC) sirukumab monotherapy compared with adalimumab monotherapy in subjects with active rheumatoid arthritis. Approximately 510 subjects will be randomly assigned in a 1:1:1 ratio to receive treatment with adalimumab 40 mg SC every 2 weeks, sirukumab 100 mg SC every 2 weeks, or 50 mg SC every 4 weeks, with approximately 170 subjects per treatment group. At Week 16, subjects in all treatment groups who have \< 20% improvement from baseline in both swollen and tender joint counts will qualify for early escape. The expected duration of the study is 68 weeks. This includes 52 weeks of treatment with study agent and 16 weeks of safety follow-up after the last study agent administration. The study will end when the last subject completes the last scheduled visit (Week 68 visit or completes the 16 week safety follow-up, whichever is later). Subject safety will be monitored through the end of the study.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • Rheumatoid arthritis
  • CNTO 136
  • Sirukumab
  • Adalimumab
  • HUMIRA®
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening
  • Have moderately to severely active RA with at least 8 of 68 tender joints and 6 of 66 swollen joints, at screening and at baseline
  • Have previous or current treatment with methotrexate (MTX) and are considered intolerant to MTX, and/or are considered inappropriate for treatment with MTX, (including MTX-naïve subjects for whom it is inappropriate to administer MTX) and/or an inadequate responder to methotrexate
  • Must not have received MTX or any other non-biologic DMARD including but not limited to sulfasalazine, hydroxychloroquine, chloroquine, and bucillamine for at least 2 weeks prior to the first administration of the study agent
  • C-reactive protein >= 10.00 mg/L or erythrocyte sedimentation rate >=28 mm/hr at screening

Exclusion criteria

Exclusion Criteria:

  • Has Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Has ever received biologic therapy for RA, including but not limited to the following: TNF-alpha inhibitors, tocilizumab, rituximab, anakinra, abatacept
  • Has ever used tofacitinib therapy or any other JAK inhibitor
  • Has received intra-articular, intramuscular, or IV for RA, including adrenocorticotrophic hormone during the 4 weeks prior to first study agent administration
  • Has received leflunomide within 24 months before the first study agent administration and has not undergone a drug elimination procedure, unless the M1 metabolite is measured and is undetectable
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
559 participants (actual)

Study arms

  • Experimental
    Group 1 (adalimumab 40 mg)

    Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have \< 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.

    Biological: adalimumab 40 mg

  • Experimental
    Group 2 (sirukumab 100 mg)

    Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (\< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).

    Biological: sirukumab 100 mg · Drug: Placebo

  • Experimental
    Group 3 (sirukumab 50 mg)

    Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have \< 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).

    Biological: sirukumab 50 mg · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24

    The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst).

    Time frame: Baseline and Week 24

  2. Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24

    The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>= 50% improvement in 3 of following 5 assessments: subject's assessment of pain using Visual Analog Scale (VAS) (0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, \[0=no arthritis activity to 10=extremely active arthritis\]), participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 24

    The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst). The DAS28 (ESR) remission is defined as a DAS28 (ESR) value of less than 2.6 at a visit.

    Time frame: Week 24

  2. Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24

    The ACR 20 Response is defined as \>= 20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20% improvement in 3 of following 5 assessments: subject's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, subject's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum CRP.

    Time frame: Week 24

07

Results

Posted Sep 14, 2017

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab 40 mgSirukumab 50 mgSirukumab 100 mg
Started186186187
Completed149134145
Not completed375242
Withdrew: Adverse event142317
Withdrew: Death011
Withdrew: Lack of efficacy744
Withdrew: Lost to follow-up021
Withdrew: Physician decision120
Withdrew: Pregnancy122
Withdrew: Withdrawal by subject111011
Withdrew: Other386

Outcome measures

PrimaryChange From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24

The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24
units on a scaleAdalimumab 40 mgSirukumab 50 mgSirukumab 100 mg
Baseline6.89 ± 0.8516.90 ± 0.8816.91 ± 0.863
Change from Baseline at Week 24-2.19 ± 1.437-2.58 ± 1.524-2.96 ± 1.58
Statistical analysis
  • Adalimumab 40 mg vs Sirukumab 100 mg · ANCOVA · p = < 0.001 · Ls mean difference: -0.76 · 95% CI -1.07 to -0.46
  • Adalimumab 40 mg vs Sirukumab 50 mg · ANCOVA · p = =0.013 · Least square (ls) mean difference: -0.39 · 95% CI -0.69 to -0.08
PrimaryPercentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24

The ACR 50 Response is defined as greater than or equal to (\>=) 50 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>= 50% improvement in 3 of following 5 assessments: subject's assessment of pain using Visual Analog Scale (VAS) (0-10 millimeter \[mm\], 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, \[0=no arthritis activity to 10=extremely active arthritis\]), participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24
Percentage of participantsAdalimumab 40 mgSirukumab 50 mgSirukumab 100 mg
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 2431.726.935.3
Statistical analysis
  • Adalimumab 40 mg vs Sirukumab 50 mg · Cochran-Mantel-Haenszel · p = 0.306 · Percentage difference: -4.8 · 95% CI -14.1 to 4.4
  • Adalimumab 40 mg vs Sirukumab 100 mg · Cochran-Mantel-Haenszel · p = 0.464 · Percentage difference: 3.6 · 95% CI -6 to 13.1
SecondaryPercentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 24

The Disease Activity Index Score 28 using ESR \[DAS28 (ESR)\] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity. The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities. The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst). The DAS28 (ESR) remission is defined as a DAS28 (ESR) value of less than 2.6 at a visit.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 24
Percentage of participantsAdalimumab 40 mgSirukumab 50 mgSirukumab 100 mg
Percentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 247.512.920.3
Statistical analysis
  • Adalimumab 40 mg vs Sirukumab 50 mg · Cochran-Mantel-Haenszel · p = 0.086 · Percentage difference: 5.4 · 95% CI -0.7 to 11.4
  • Adalimumab 40 mg vs Sirukumab 100 mg · Cochran-Mantel-Haenszel · p = < 0.001 · Percentage difference: 12.8 · 95% CI 5.9 to 19.7
SecondaryPercentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24

The ACR 20 Response is defined as \>= 20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and \>=20% improvement in 3 of following 5 assessments: subject's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, \[0 mm=no pain to 100 mm=worst possible pain\]), physician's global assessment of disease activity using VAS, subject's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas. The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum CRP.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24
Percentage of participantsAdalimumab 40 mgSirukumab 50 mgSirukumab 100 mg
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 2456.553.858.8
Statistical analysis
  • Adalimumab 40 mg vs Sirukumab 50 mg · Cochran-Mantel-Haenszel · p = 0.603 · Percentage difference: -2.7 · 95% CI -12.8 to 7.4
  • Adalimumab 40 mg vs Sirukumab 100 mg · Cochran-Mantel-Haenszel · p = 0.644 · Percentage difference: 2.4 · 95% CI -7.6 to 12.3

Adverse events

Collected over Screening, up to Week 68. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 40 mg q2w Only—15/173 (8.7%)71/173 (41%)
Adalimumab 40 mg q2w Then 40 mg q1w—1/13 (7.7%)3/13 (23.1%)
Adalimumab 40 mg—16/186 (8.6%)74/186 (39.8%)
Sirukumab 50 mg q4w Only—23/160 (14.4%)79/160 (49.4%)
Sirukumab 50 mg q4w Then 100 mg q2w—6/26 (23.1%)13/26 (50%)
Sirukumab 50 mg—29/186 (15.6%)92/186 (49.5%)
Sirukumab 100 mg—22/187 (11.8%)86/187 (46%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventAdalimumab 40 mg q2w OnlyAdalimumab 40 mg q2w Then 40 mg q1wAdalimumab 40 mgSirukumab 50 mg q4w OnlySirukumab 50 mg q4w Then 100 mg q2wSirukumab 50 mgSirukumab 100 mg
Sinus node dysfunctionCardiac disorders0/1731/131/1860/1600/260/1860/187
Coronary artery diseaseCardiac disorders0/1730/130/1860/1601/261/1860/187
Diverticular perforationGastrointestinal disorders0/1730/130/1860/1601/261/1860/187
ErysipelasInfections and infestations1/1730/131/1860/1601/261/1860/187
HaemarthrosisMusculoskeletal and connective tissue disorders0/1730/130/1860/1601/261/1860/187
OsteonecrosisMusculoskeletal and connective tissue disorders0/1730/130/1860/1601/261/1860/187
SynovitisMusculoskeletal and connective tissue disorders0/1730/130/1860/1601/261/1860/187
Gliomatosis cerebriNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1730/130/1860/1601/261/1860/187
Skin ulcerSkin and subcutaneous tissue disorders0/1730/130/1860/1601/261/1860/187
Atrial fibrillationCardiac disorders1/1730/131/1862/1600/262/1860/187
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAdalimumab 40 mg q2w OnlyAdalimumab 40 mg q2w Then 40 mg q1wAdalimumab 40 mgSirukumab 50 mg q4w OnlySirukumab 50 mg q4w Then 100 mg q2wSirukumab 50 mgSirukumab 100 mg
Injection site erythemaGeneral disorders13/1730/1313/18615/1602/2617/18633/187
Aspartate aminotransferase increasedInvestigations11/1730/1311/1869/1604/2613/18620/187
HeadacheNervous system disorders9/1732/1311/18610/1601/2611/18613/187
HypertensionVascular disorders9/1731/1310/1868/1604/2612/1868/187
Alanine aminotransferase increasedInvestigations12/1730/1312/18618/1603/2621/18624/187
Rheumatoid arthritisMusculoskeletal and connective tissue disorders17/1730/1317/18617/1603/2620/18615/187
NeutropeniaBlood and lymphatic system disorders4/1730/134/18616/1601/2617/18611/187
NasopharyngitisInfections and infestations16/1730/1316/1869/1601/2610/1869/187
Injection site pruritusGeneral disorders8/1730/138/1866/1600/266/18617/187
BronchitisInfections and infestations4/1730/134/1868/1602/2610/1868/187

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adalimumab 40 mgSirukumab 50 mgSirukumab 100 mgTotal
<=18 years0000
Between 18 and 65 years163159164486
>=65 years23272373
Age, Continuous
Age, Continuous(years)Adalimumab 40 mgSirukumab 50 mgSirukumab 100 mgTotal
Mean52.6 ± 12.1552.5 ± 12.4649.8 ± 12.3151.6 ± 12.36
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mgSirukumab 50 mgSirukumab 100 mgTotal
Female156157154467
Male30293392
Region of Enrollment
Region of Enrollment(participants)Adalimumab 40 mgSirukumab 50 mgSirukumab 100 mgTotal
Bulgaria1102
Chile52310
Colombia76114
Germany51511
Hungary0123
Lithuania1215936
Mexico35311
Moldova26412
Poland21172058
Romania45413
Russian Federation30293392
Serbia20192665
South Africa89724
Spain1102
Ukraine423739118
United States25323188
08

Study locations

109 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Arvin, California, United States
  • El Cajon, California, United States
  • Huntington Beach, California, United States
  • Pleasanton, California, United States
  • Thousand Oaks, California, United States
  • Tustin, California, United States
  • Whittier, California, United States
  • Newark, Delaware, United States
  • Aventura, Florida, United States
  • Dunedin, Florida, United States
  • Miami, Florida, United States
  • New Port Richey, Florida, United States
  • Palm Harbor, Florida, United States
  • Plantation, Florida, United States
  • Tampa, Florida, United States
  • Kansas City, Kansas, United States
  • Elizabethtown, Kentucky, United States
  • Paducah, Kentucky, United States
  • Frederick, Maryland, United States
  • Wheaton, Maryland, United States
  • Saint Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Salisbury, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Dayton, Ohio, United States
  • Portland, Oregon, United States
  • Duncansville, Pennsylvania, United States
  • Wexford, Pennsylvania, United States
  • Wyomissing, Pennsylvania, United States
  • Jackson, Tennessee, United States
  • Nashville, Tennessee, United States
  • Austin, Texas, United States
  • Carrollton, Texas, United States
  • Corpus Christi, Texas, United States
  • Cypress, Texas, United States
  • Lubbock, Texas, United States
  • McKinney, Texas, United States
  • Mesquite, Texas, United States
  • Chesapeake, Virginia, United States
  • Clarksburg, West Virginia, United States
  • Ruse, Bulgaria
  • Sofia, Bulgaria
  • Puerto Montt, Chile
  • Temuco, Chile
  • Barranquilla, Colombia
  • Bogota, Colombia
  • Bucaramanga, Colombia
  • Bad Doberan, Germany
  • Berlin, Germany
  • Köln, Germany
  • Ratingen, Germany
  • Vogelsang-Gommern, Germany
  • Debrecen, Hungary
  • Gödöllő, Hungary
  • Klaipeda, Lithuania
  • Siauliai, Lithuania
  • Vilnius, Lithuania
  • Chihuahua, Mexico
  • Guadalajara, Mexico
  • Jalisco, Mexico
  • Mexicali, Mexico
  • Chisinau, Moldova, Republic of
  • Bydgoszcz, Poland
  • Bytom, Poland
  • Krakow, Poland
  • Lublin, Poland
  • Nadarzyn, Poland
  • Poznan, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Bucharest, Romania
  • Constanta, Romania
  • Ploiesti, Romania
  • Arkhangelsk, Russian Federation
  • Kazan, Russian Federation
  • Kemerovo, Russian Federation
  • Kursk, Russian Federation
  • Moscow, Russian Federation
  • Novosibirsk, Russian Federation
  • Petrozavodsk, Russian Federation
  • Ryazan, Russian Federation
  • Saint Petersburg, Russian Federation
  • St Petersburg, Russian Federation
  • St-Petersburg, Russian Federation
  • Tomsk, Russian Federation
  • Tver, Russian Federation
  • Vladimir, Russian Federation
  • Yaroslavl, Russian Federation
  • Belgrade, Serbia
  • Novi Sad, Serbia
  • Zemun, Serbia
  • Cape Town, South Africa
  • Durban, South Africa
  • Kempton Park, South Africa
  • Stellenbosch, South Africa
  • Coruna, Spain
  • Madrid, Spain
  • Chernihiv, Ukraine

Showing the first 100 of 109 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Taylor PC, Schiff MH, Wang Q, Jiang Y, Zhuang Y, Kurrasch R, Daga S, Rao R, Tak PP, Hsu B. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naive patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Ann Rheum Dis. 2018 May;77(5):658-666. doi: 10.1136/annrheumdis-2017-212496. Epub 2018 Feb 26. PubMed 29483080 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Aug 2016, 28 months.

Results were first posted in Sep 2017, 1 year after primary completion. A results delay was requested in Jul 2016.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 28 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Dec 24, 2013
StartActual
Apr 4, 2014
Primary completionActual
Aug 17, 2016
CompletionActual
Aug 17, 2016
Results delay requested
Jul 4, 2016
Results first posted
Sep 14, 2017
Last update
Oct 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02019472
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 24, 2013
Start date
Apr 4, 2014
Primary completion
Aug 17, 2016
Completion
Aug 17, 2016
Results posted
Sep 14, 2017
Last update
Oct 26, 2017

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Sirukumab

Start the discussion